Verruca Treatment
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Verruca Treatment Family Health Verruca Treatment Numark Verruca Treatment Tesco Verruca Treatment
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Salicylic acid BP 50% w/w
3 PHARMACEUTICAL FORM
Cutaneous paste
4 CLINICAL PARTICULARS
4.1 Therapeutic indications
For the destruction of plantar warts.
4.2 Posology and method of administration
For external use.
Adults, the elderly and children
Thoroughly cleanse the surrounding area with soap or surgical spirit using cotton wool or a piece of clean material which should be disposed of carefully after use.
Apply a protective ring-pad centrally over the verruca and place a small quantity of the paste into the central hole of the ring. Cover with a plaster and leave in place for 2-3 days. Repeat as necessary using a fresh ring-pad and plaster each time.
4.3 Contraindications
Diabetes.
4.4 Special warnings and precautions for use
• Discontinue use if painful irritation develops
• Keep away from the eyes
• Keep out of the reach of children
• Wash your hands immediately after use
• If the verruca does not separate from the surrounding healthy tissue after two weeks, consult your doctor or state registered chiropodist
• If the ointment comes into contact with healthy skin, or the eyes, flush immediately with cold water
• Diabetics should only use this product under medical supervision
• This product is intended for the treatment of small round shaped verrucas, no larger than the protective ring pads. If your verruca is larger than this or is irregular in shape, do not use this product. Instead consult your doctor or state registered chiropodist
4.5 Interaction with other medicinal products and other forms of interaction
None known.
4.6 Pregnancy and lactation
No reason is known why this product may not be used in this condition.
Effects on ability to drive and use machines
None known.
4.8 Undesirable effects
May cause dermatitis. Symptoms of acute systemic salicylate poisoning have been reported after the application of salicylic acid ointments and solution to large areas of the body. This is unlikely to happen when treating plantar warts.
4.9 Overdose
Either from oral consumption of contents of tube or from excessive application:
Empty the stomach (if ingested) and determine the plasma salicylate concentration. If the concentration is less than 350mg/L in children or 450mg/L in adults, simply increase oral fluid intake. If the concentration is higher, treat patient by forced alkaline diuresis.
5 PHARMACOLOGICAL PROPERTIES
5.1 Pharmacodynamic properties
A kerolytic agent.
5.2
Pharmacokinetic properties
Not applicable.
Preclinical safety data
None stated.
6 PHARMACEUTICAL PARTICULARS
6.1 List of excipients
White soft paraffin BP, liquid paraffin BP.
6.2 Incompatibilities
None known.
6.3 Shelf life
36 months unopened.
6.4 Special precautions for storage
None.
6.5 Nature and contents of container
5g of product contained in a 12.7mm x 88mm internally lacquered collapsible aluminium tube with a 60 eye ointment cap. Packed into a carton with 6 corn rings 1/8” x 17mm CD and 6 self adhesive plasters 5 x 3cm.
6.6
Special precautions for disposal
Not applicable.
7 MARKETING AUTHORISATION HOLDER
AYRTON SAUNDERS LIMITED NORTH WAY
WALWORTH INDUSTRAIL ESTATE
ANDOVER
SP10 5AZ
UNITED KINGDOM
8 MARKETING AUTHORISATION NUMBER(S)
PL 16431/0042
9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE
AUTHORISATION
3rd March 1978 / 17th April 1996
10 DATE OF REVISION OF THE TEXT
29/01/2009
11 DOSIMETRY (IF APPLICABLE)
12 INSTRUCTIONS FOR PREPARATION OF
RADIOPHARMACEUTICALS (IF APPLICABLE)